GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCM Biotech International Corp (ROCO:4169) » Definitions » Net-Net Working Capital

TCM Biotech International (ROCO:4169) Net-Net Working Capital : NT$8.57 (As of Jun. 2024)


View and export this data going back to 2012. Start your Free Trial

What is TCM Biotech International Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

TCM Biotech International's Net-Net Working Capital for the quarter that ended in Jun. 2024 was NT$8.57.

The industry rank for TCM Biotech International's Net-Net Working Capital or its related term are showing as below:

ROCO:4169's Price-to-Net-Net-Working-Capital is ranked worse than
66.33% of 903 companies
in the Biotechnology industry
Industry Median: 4.21 vs ROCO:4169: 7.01

TCM Biotech International Net-Net Working Capital Historical Data

The historical data trend for TCM Biotech International's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCM Biotech International Net-Net Working Capital Chart

TCM Biotech International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.40 -0.31 -0.45 0.09 8.49

TCM Biotech International Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.09 0.16 8.49 8.57

Competitive Comparison of TCM Biotech International's Net-Net Working Capital

For the Biotechnology subindustry, TCM Biotech International's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TCM Biotech International's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCM Biotech International's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where TCM Biotech International's Price-to-Net-Net-Working-Capital falls into.



TCM Biotech International Net-Net Working Capital Calculation

TCM Biotech International's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(504.131+0.75 * 232.395+0.5 * 181.734-267.88
-0-0)/59.0486
=8.49

TCM Biotech International's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2024 is calculated as

Net-Net Working Capital(Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(573.321+0.75 * 107.991+0.5 * 146.583-221.776
-0-0)/59.0486
=8.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


TCM Biotech International  (ROCO:4169) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


TCM Biotech International Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of TCM Biotech International's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


TCM Biotech International Business Description

Traded in Other Exchanges
N/A
Address
No. 97, Sec. 1, Xintai 5th Road, Xizhi District, Neihu District, Taipei, TWN, 221
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.

TCM Biotech International Headlines

No Headlines